Gonadorelin

What it is

Gonadorelin is the native ten-amino-acid GnRH sequence, listed by FDA under UNII 9O7312W37G. Acetate and hydrochloride are mapped forms. Longer-acting GnRH analogs are different drugs, not aliases with longer half-lives.

Human findings depend on specified salt, finished product, route, and especially exposure pattern. Pulsatile pump-delivered native GnRH evidence does not automatically transfer to continuous exposure, a bolus product, a GnRH analog, a veterinary product, or an unidentified product.

Why people care

Interest spans fertility and circulating testosterone or wellness claims. The central evidence problem is that native GnRH, its salts, longer-acting GnRH analogs, pulsatile versus continuous exposure, historical human products, veterinary products, and unidentified online products are not interchangeable.

What humans actually show

Pulsatile native GnRH/gonadorelin has human endocrine and fertility evidence in selected deficiency populations, but that evidence is regimen- and population-specific. FDA's historical record includes the diagnostic-use Lutrepulse pulsatile-pump kit as well as Factrel injection; Drugs@FDA lists the identified Factrel presentations as discontinued, no Lutrepulse label was located, and current veterinary products and a 2026 warning-letter product are separate records.

• other human — Eight patients with anovulation attributed to relative or absolute endogenous GnRH deficiency, treated over 23 cycles; Route: Pulsatile GnRH delivered by portable pump; Outcome: Pituitary-ovarian activation, ovulation, pregnancy, and live birth: Ovulation occurred in 20 of 23 cycles; five of eight patients conceived, with seven pregnancies and four full-term deliveries reported. The seam: Uncontrolled study with eight patients; Published in 1983; Selected hypothalamic-deficiency population; Abstract does not resolve every salt and finished-product detail; Does not establish a general testosterone, wellness, or product-identity conclusion.
• other human — Eighteen women with hypothalamic amenorrhea treated over 30 cycles; Route: Pulsatile intravenous GnRH in a physiological-frequency study; Outcome: Ovulation, pregnancy, endocrine response, and follicular maturation: The study reported ovulation and pregnancies in both exposure groups; multiple-follicle maturation occurred in five of 20 cycles in the higher-exposure group. The seam: Small, non-placebo-controlled physiological study; Regimen-specific results; Cannot transfer to another population, salt, product, route, or combination; Study details are evidence, not reader instructions.
• other human — 141 infertility patients with functional hypothalamic amenorrhea or congenital hypogonadotropic hypogonadism treated from 2004 through 2022; Route: Pulsatile GnRH therapy; Outcome: Ongoing pregnancy per initiated cycle: Ongoing pregnancy rates were 21.5% in functional hypothalamic amenorrhea and 22% in congenital hypogonadotropic hypogonadism. The seam: Retrospective, nonrandomized, single-center cohort; Comparison between diagnoses rather than treatment versus no treatment; Does not authenticate a U.S. finished product; Does not support testosterone, bodybuilding, anti-aging, or general-wellness claims.

Mechanistic and nonhuman evidence

• mechanistic — FDA sequence identity plus human pituitary-ovarian biomarker responses; Route: Substance record and specified pulsatile human exposures; Outcome: GnRH identity and gonadotropin/ovarian response: The sources support gonadorelin as native GnRH and show that specified pulsatile exposures can provoke pituitary gonadotropin and ovarian responses. The seam: Hormone release and follicular response are not automatically clinical outcomes; Mechanism does not establish broad treatment benefit; Exposure pattern and product identity remain material.

FDA and U.S. status

An FDA CDER review records two historical native-GnRH approvals for diagnostic use: Factrel injection (gonadorelin hydrochloride, NDA 018123, approved 1982) and the Lutrepulse pulsatile-pump kit (gonadorelin acetate, NDA 019687, approved 1989). Drugs@FDA lists the three Factrel presentations as discontinued, and no Lutrepulse label was located in the reviewed record. Historical approval does not establish current availability. A 503B nomination, FDA substance record, veterinary application, warning-letter product, or shared product name does not authenticate another product.

Risks and warning limits

• human trial: A small human dose-response study reported multiple-follicle maturation in five of 20 cycles in its higher-exposure group.
• not characterized: A complete contemporary labeled warning, contraindication, pregnancy, rare-event, and interaction profile was not established because the identified human Factrel presentations are discontinued, no Lutrepulse label was located, and no current marketed-human label was identified.
• case report or safety signal: FDA warned that the specific unapproved online injectable product it reviewed could pose additional harm because injection bypasses defenses against toxins and microorganisms; this is a product-quality and route warning, not an event rate for verified gonadorelin.

What remains unknown

• Whether any currently marketed human product corresponds to the historical Factrel or Lutrepulse applications; the identified Factrel presentations are discontinued, and no Lutrepulse label was located.
• A complete contemporary labeled safety and interaction profile for a marketed human gonadorelin product was not located.
• Long-term clinical outcomes outside selected infertility populations and specified pulsatile exposure patterns remain insufficiently characterized in this packet.
• The exact salt and finished-product details remain unresolved for papers whose abstracts report only GnRH.

Product identity and quality limits

• FDA's UNII record defines a substance identity but explicitly does not imply regulatory review or approval of a product.
• Historical human Factrel, historical Lutrepulse, current veterinary Factrel, gonadorelin acetate, gonadorelin hydrochloride, and a product labeled only gonadorelin are separate identity and regulatory records.
• FDA's 503B Category 1 nomination means gonadorelin acetate is under evaluation; it does not establish that a compounded preparation is approved, equivalent, sterile, stable, or clinically supported.
• FDA found no approved application in effect for the specific online gonadorelin product it reviewed in 2026, defeating identity transfer from the historical human application to that product.

What has been studied together

• Testosterone, hCG, or other human hormone regimens — no direct evidence: The focused human PubMed and ClinicalTrials.gov pass identified selected pulsatile GnRH studies and diagnostic records, not controlled outcome evidence for the online adjunct claims scoped here. FDA recorded testosterone-production claims for one unapproved product; that does not validate a combination. Missing evidence does not establish safety.

What people are hearing

These are claims this profile checks, not established conclusions.

• Claim under review: “Historical Factrel approval means any product labeled gonadorelin is FDA approved.”
• Claim under review: “Pulsatile GnRH fertility studies prove a general testosterone or wellness benefit.”
• Claim under review: “Gonadorelin is interchangeable with every longer-acting GnRH agonist.”

Questions readers raise

• No reproducible community sample was collected for this profile.

The community-signal layer is not efficacy or safety evidence. Its current limits are:

• No reproducible community sample has been collected for this profile.
• Self-reports would be subject to selection and reporting bias.
• The identity, salt, route, and exposure pattern of a product described in a self-report could not be verified.
• Concurrent hormones, medicines, behaviors, and health conditions could confound an anecdote.
• Reported endocrine and fertility outcomes could not be independently verified.
• Anecdotes cannot establish efficacy, safety, approval, product identity, or interaction compatibility.

What would change this answer

• A current FDA human-product record and approved labeling would change the historical-product and labeled-warning boundary.
• Controlled human outcome trials in the exact population, formulation, exposure pattern, and combination being claimed would change the current evidence boundary.
• Finished-product analytical and regulatory records could change the current inability to transfer study or historical-product identity to another product.

Sources and records

• WADA — 2026 Prohibited List

• FDA GSRS substance record for gonadorelin — U.S. Food and Drug Administration
• Drugs@FDA exact active-ingredient API search for gonadorelin hydrochloride — U.S. Food and Drug Administration
• Drugs@FDA application record for Lutrepulse, NDA 019687 — U.S. Food and Drug Administration
• FDA CDER review recording historical Factrel diagnostic approval — U.S. Food and Drug Administration
• FDA 503B bulk drug substances nomination categories — U.S. Food and Drug Administration
• FDA June 17, 2026 warning letter concerning an online gonadorelin product — U.S. Food and Drug Administration
• FDA resource on gonadorelin-containing animal drugs — U.S. Food and Drug Administration
• Pulsatile administration of low-dose gonadotropin-releasing hormone: ovulation and pregnancy in women with hypothalamic amenorrhea — JAMA / PubMed
• Intravenous administration of pulsatile gonadotropin-releasing hormone in hypothalamic amenorrhea: effects of dosage — Journal of Clinical Endocrinology and Metabolism / PubMed
• Pulsatile gonadotropin-releasing hormone therapy in functional hypothalamic amenorrhea and congenital hypogonadotropic hypogonadism — Fertility and Sterility / PubMed
• ClinicalTrials.gov intervention search for gonadorelin — U.S. National Library of Medicine
• PubMed title search for gonadorelin — U.S. National Library of Medicine